Embecta Corp
EMBC
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
702.1% upsideUndervalued by 702.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $184.51 Million |
|---|---|
| Enterprise Value | $1.36 Billion |
| Dividend Yield | $0.46 (14.79%) |
| Earnings per Share | $1.64 |
| Beta | 0.81 |
| Outstanding Shares | 58,309,000 |
Return
| Return on Equity | -17.87% |
|---|---|
| Return on Assets | 10.87% |
| Return on Invested Capital | 35.20% |
Valuation & Multiples
| P/E Ratio | 1.63 |
|---|---|
| PEG | -1.39 |
| Price to Sales | 0.18 |
| Price to Book Ratio | -0.28 |
| Enterprise Value to Revenue | 1.31 |
| Enterprise Value to EBIT | 4.95 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 1 |
| Debt to Equity | -2.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2057▲ 92.65% |
|---|---|
| Total Calls | 101,600▼ 49.35% |
| Total Puts | 122,500▲ 118.75% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 103.93%▲ 4.09% |
|---|---|
| Total Invested | $536.06M▼ 22.49% |
| Investors Holding | 340▼ 26.00% |
ESG Score
No data
About Embecta Corp
Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policy, which is the single most important driver of pricing and market access for diabetes care products.
Controls the actual cash flow to the FDA and VA, directly determining the speed of product approvals and government purchasing volume.
Directly oversees the FDA, which regulates Embecta's products, and develops legislation regarding healthcare access and labor costs.
Diabetes disproportionately affects the elderly; this committee's oversight of drug pricing and healthcare quality creates significant headline risk and regulatory pressure.
The VA is a major purchaser of medical supplies; decisions on veteran healthcare spending directly impact revenue for insulin delivery device manufacturers.